Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 14 LLY Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
May 14 LLY Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs
May 14 LLY Lilly target price raised at Argus on Mounjaro, Zepbound sales
May 14 LLY 2 Top Pharma Stocks That Just Keep Getting Better and Better
May 14 LLY Is Eli Lilly's Latest Deal a Gamechanger?
May 14 LLY 3 Magnificent Stocks That Are Passive Income Machines
May 13 AXSM 15 Most Depressed States in the US
May 13 LLY Wegovy weight loss sustained for four years in trial, Novo Nordisk says
May 13 LLY Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
May 13 LGND Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade
May 13 LGND Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
May 13 LGND Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
May 12 NHC 15 Best Places in Oregon For A Couple To Live On Only Social Security
May 11 AXSM Prediction: These 2 Growth Stocks Could Triple By 2030
May 11 LLY 1 No-Brainer Growth Stock to Buy and Hold
May 11 LLY Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
May 10 SAVA Cassava swings to Q1 profit as more patients finish simufilam phase 3 trials
May 10 SAVA Cassava Sciences GAAP EPS of -$0.43 beats by $0.03
May 10 SAVA Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
May 10 LLY Lilly could partner with Cipla to market GLP-1 drugs in India - report
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags